Alagille Syndrome Market

Key Highlights

• DelveInsight’s analyst projects that the total prevalent cases of Alagille Syndrome (ALGS) in the 7MM were ~17,883 in 2023 and these cases are going to increase during the forecast period (2024–2034). This increase in growth can be attributed to growing awareness and population growth ultimately leading to an increase in the prevalence of ALGS.
• According to DelveInsight's analysis, it is projected that approximately 38% of the total prevalent cases of Alagille Syndrome (ALGS) in the 7MM were in the United States. As per the estimations, it indicates that in 2023, the EU4 and the UK collectively represented nearly 9,819 prevalent cases of ALGS.
• According to DelveInsight’s analysis, the total prevalent cases of ALGS in the US were found to be nearly 6,824 in 2023 and are estimated to increase with a significant CAGR throughout the forecast period.
• As per DelveInsight’s estimates, Japan accounted for nearly 7% of the total prevalent cases of ALGS in the 7MM in 2023.

DelveInsight’s “Alagille Syndrome (ALGS) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Alagille Syndrome, historical and forecasted epidemiology of Alagille Syndrome in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020–2034

Alagille Syndrome Disease Understanding 

Alagille Syndrome Overview

Alagille syndrome, also known as Alagille-Watson syndrome, is a rare genetic disorder caused by mutations in the JAG1 or NOTCH2 gene. Predominantly involving JAG1 on chromosome 20, this autosomal dominant condition affects multiple organ systems. Symptoms typically appear within the first two years of life and include bile duct paucity, cholestasis, jaundice, poor weight gain, severe itching, congenital heart defects, heart murmurs, vertebral anomalies, distinctive facial features, and ocular abnormalities. Around half of the cases occur de novo, meaning the mutation is not inherited from a parent. The severity of symptoms varies, with some individuals requiring liver transplantation due to progressive liver damage. 

Alagille Syndrome Recent Developments

• On September 23, 2024, Ipsen announced that the European Commission has granted approval for Kayfanda® (odevixibat) under exceptional circumstances to treat cholestatic pruritus in patients with Alagille Syndrome (ALGS) aged 6 months and older. Kayfanda is a once-daily, non-systemic ileal bile acid transport (IBAT) inhibitor. The active ingredient, odevixibat, works by blocking the ileal bile acid transporter, leading to a reduction in serum bile acids produced by the liver.

Alagille Syndrome Diagnosis

The diagnosis of ALGS is complex due to its highly variable symptoms. It involves identifying characteristic symptoms through detailed patient history, thorough clinical evaluation, and specialized tests. Key diagnostic tools include liver biopsy to detect bile duct paucity, although this hallmark feature might not always be present in infants. Diagnosis is often suspected if an individual exhibits three of five clinical findings: liver disease or cholestasis, heart defects, skeletal abnormalities, ophthalmologic issues, and distinctive facial features. Additional tests, such as blood tests, eye examinations, spine x-rays, abdominal ultrasounds, and heart function evaluations, support the diagnosis. Molecular genetic testing for JAG1 or NOTCH2 mutations can confirm the diagnosis, although some cases may not reveal these mutations.

Further details related to diagnosis are provided in the report…

Alagille Syndrome Epidemiology

For the purpose of designing the patient-based model for Alagille Syndrome (ALGS), the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Alagille Syndrome, Gender-Specific Prevalent Cases of Alagille Syndrome, Age-specific Prevalent Cases of Alagille Syndrome, and Type-specific Prevalent Cases of Alagille Syndrome in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. 

• The highest proportion of ALGS cases was reported in Germany among the EU4 and the UK, while the lowest number of cases was found in Spain.
• The Gender-specific Cases of ALGS in the US were ~3,846 for males and ~2,978 for females in 2023 and are expected to increase within the forecast period (2024–2034). 
• According to the analysis performed by DelveInsight's experts, the Age-specific Cases of ALGS were categorized into 0-0.5 years, 0.5-10 years, 11-20 years, and >20 years The higher number of cases (~4,436) was accounted for by the 0.5-10 year age group in 2023 in the US.
• The Prevalence of ALGS Based on the Type of ALGS was categorized into Patients with Chronic Cholestasis and Patients without Cholestasis. According to DelveInsight estimates, a higher number of patients were estimated in Patients with Chronic Cholestasis, with approximately 1,177 cases in 2023 in Japan.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence. 

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Michigan Hospital; Department of Surgery, UCSF; University Hospital, Münster, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of Alagille Syndrome, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Alagille Syndrome Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Prevalent Cases of Alagille Syndrome
• Gender-Specific Prevalent Cases of Alagille Syndrome
• Age-specific Prevalent Cases of Alagille Syndrome
• Type-specific Prevalent Cases of Alagille Syndrome 

Alagille Syndrome Report Key Strengths

• 11 years Forecast
• The 7MM Coverage 
• Alagille Syndrome Epidemiology Segmentation 

Alagille Syndrome Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Alagille Syndrome? What will be the growth opportunities across the 7MM concerning the patient population of Alagille Syndrome?
• What is the historical and forecasted Alagille Syndrome patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Why are the diagnosed prevalent cases of ALGS in Japan lower than in the US?
• Which country has a high patient share for ALGS?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Alagille Syndrome prevalence cases in varying geographies over the coming years.
• A detailed overview of Gender and Age-specific prevalence of ALGS, and prevalence of ALGS based on type of ALGS.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.